SCHEMBL15079096

SCHEMBL15079096

CC[Si](C#CC(O)(C#C[Si](CC)(CC)CC)c1ccccc1)(CC)CC

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KCNN4 O15554 1/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ APOBEC3A P31941 1/20 0.34
▸ APOBEC3G Q9HC16 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15077772 0.74 CACNA2D1 (0.44) ALDH1A1KDM4ECYP1A2CYP2C19PABPC1
SCHEMBL15077740 0.71 CYP1A2 (0.41) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL29213040 0.70 MAPT (0.41) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL29213002 0.69 CACNA2D1 (0.40) ALDH1A1KDM4ECYP1A2CYP2C19PABPC1
SCHEMBL29213035 0.69 NR1H2 (0.35) ALDH1A1KDM4EPABPC1APOBEC3AAPOBEC3G
SCHEMBL29212985 0.66 CACNA2D1 (0.40) ALDH1A1KDM4ECYP1A2CYP2C19PABPC1
SCHEMBL10054127 0.66 CYP2C19 (0.40) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL3573293 0.66 APP (0.48) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
Propane SCHEMBL27957403 0.64 CYP2C19 (0.46) ALDH1A1CYP1A2CYP2C9CYP2C19KCNN4
SCHEMBL734904 0.63 DHFR (0.41) ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206100-B2 Route to synthetic analogues of Rocaglamide and Aglafoline using cascade transformations initiated by oxy-cope rearrangement of bis-alkynes The Florida State University Research Foundation, Inc. (US) 2015-12-08 — — US disclosed
US-20130165683-A1 NEW ROUTE TO SYNTHETIC ANALOGUES OF ROCAGLAMIDE AND AGLAFOLINE USING CASCADE TRANSFORMATIONS INITIATED BY OXY-COPE REARRANGEMENT OF BIS-ALKYNES THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION INC. 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165683-A1 NEW ROUTE TO SYNTHETIC ANALOGUES OF ROCAGLAMIDE AND AGLAFOLINE USING CASCADE TRANSFORMATIONS INITIATED BY OXY-COPE REARRANGEMENT OF BIS-ALKYNES COASY, RIMKLA, ACSL3 ALDH1A1 1262/4885KDM4E 3581/4885CYP1A2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback